Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood tests may help predict ovarian cancer treatment success

NCT ID NCT07678008

Knowledge-focused Sponsor: Aya Ahmed Nasser Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researchers will review medical records of 80 patients who received chemotherapy before surgery. The goal is to see if these markers can help forecast how long patients live without the disease worsening and whether surgery will be successful.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which patients with advanced ovarian cancer will respond to chemotherapy and surgery, potentially guiding more personalized treatment plans.
What could go wrong
This is a small, retrospective study, so results may not apply to all patients. The markers studied are not yet proven to be reliable enough for routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of female patients diagnosed with advanced epithelial ovarian cancer (specifically stage III or IV high-grade serous ovarian carcinoma) who were managed and followed up at Sohag University Hospital and Sohag Cancer Center, Egypt. Eligible participants are those who underwent a standard treatment protocol comprising platinum-based neoadjuvant chemotherapy followed by interval cytoreductive surgery between January 2022 and December 2025, and whose medical records contain comprehensive baseline hematological and tumor marker data.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged \\ge 18 years old., Histologically confirmed advanced epithelial ovarian cancer (High-Grade Serous Ovarian Carcinoma), Stage III or IV. Patients who received platinum-based neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) at Sohag University Hospital or Sohag Cancer Center between 2022 and 2025. Available complete medical records, including pre-treatment baseline CBC (for NLR and PLR calculation) and longitudinal CA-125 levels (for KELIM score estimation). Exclusion Criteria: Patients with non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord-stromal tumors). Patients who underwent primary debulking surgery (PDS) before receiving chemotherapy. Patients with concurrent active malignancies or a history of other cancers within the past 5 years. Patients with active systemic inflammatory diseases, hematological disorders, or severe infections at baseline that could interfere with baseline inflammatory markers (NLR/PLR). Incomplete or missing clinical, surgical, or follow-up data. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced ovarian cancer (stage III or IV) after neoadjuvant chemotherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian carcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced ovarian cancer (stage III or IV) after neoadjuvant chemotherapy High-grade serous ovarian carcinoma

Contacts and locations

Locations

  • Sohag university hospital

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.